Skip to main content
Clinical Trials/IRCT2014012616367N1
IRCT2014012616367N1CompletedPhase 2

Determination of effect of N acetylcysteine on pulmonary function in patients with diffuse scleroderma

Vice chancellor for research, Shiraz University of Medical Sciences0 sites24 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
24

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 100 years (—)
Sex
All

Inclusion Criteria

  • Cases of diffuse scleroderma who fulfilled the ACR criteria for systemic sclerosis that diagnosis of their disease was made less than one year ago; No evidence of fibrosis in high rsolution CT scan (HRCT)
  • Exclusion criteria:
  • Lung involvement (deterioration of disease); Not properly usage of drug; Not regularly visits by cases in intervals and appointments that were determined for them; Not toleration of drug or probable allergic reactions to it (very rare reports); Clinical or serologic evidence of other collagen vascular disease; History of exposure to known fibrogenic agents; Previous use of immunosuppressive or corticosteroid therapy for a minimum of 6 months before entering the study.

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Vice chancellor for research, Shiraz University of Medical Sciences

Similar Trials